Exploristics has announced its plans to launch an updated version of its cloud-based data analytics platform for clinical trial design, KerusCloud 2.0, by the end of the summer. KerusCloud 2.0 builds on its capability enabling more realistic clinical trial simulations thanks to a new feature that generates correlated data for sub-groups within a patient population, facilitating the investigation of precision medicine or adaptive development pathways.
For more information, click here.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.